{
    "0PQ.F": {
        "short_name": "PROQR THERAPEUTICS EO-,04",
        "long_name": "ProQR Therapeutics N.V.",
        "summary": "ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "state": null,
        "city": "Leiden",
        "zipcode": "2333 Ck",
        "website": "http://www.proqr.com",
        "market_cap": "Small Cap"
    },
    "1AE.F": {
        "short_name": "ARGENX SE EO -,10",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "state": null,
        "city": "Breda",
        "zipcode": "4811 AH",
        "website": "http://www.argenx.com",
        "market_cap": "Large Cap"
    },
    "2GH.F": {
        "short_name": "MERUS N.V.  EO -,09",
        "long_name": "Merus N.V.",
        "summary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "state": null,
        "city": "Utrecht",
        "zipcode": "3584 CM",
        "website": "http://www.merus.nl",
        "market_cap": "Small Cap"
    },
    "9EN.F": {
        "short_name": "PHARVARIS N.V.  EO -,12",
        "long_name": "Pharvaris N.V.",
        "summary": "Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "state": null,
        "city": "Leiden",
        "zipcode": "2333 CH",
        "website": "http://pharvaris.com",
        "market_cap": "Small Cap"
    },
    "ARGX.BR": {
        "short_name": "ARGENX SE",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Netherlands",
        "state": null,
        "city": "Breda",
        "zipcode": "4811 AH",
        "website": "http://www.argenx.com",
        "market_cap": "Large Cap"
    },
    "ARGX": {
        "short_name": "argenx SE",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "state": null,
        "city": "Breda",
        "zipcode": "4811 AH",
        "website": "http://www.argenx.com",
        "market_cap": "Large Cap"
    },
    "ARGX.VI": {
        "short_name": "ARGENX SE",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Netherlands",
        "state": null,
        "city": "Breda",
        "zipcode": "4811 AH",
        "website": "http://www.argenx.com",
        "market_cap": "Large Cap"
    },
    "K3P.F": {
        "short_name": "KIADIS PHARMA NV  EO -,10",
        "long_name": "Kiadis Pharma N.V.",
        "summary": "Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. It develops K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol; and K-NK003 for the treatment of patients with acute myeloid leukemia relapse/refractory. The company also develops K-NK-ID101 for the treatment of COVID-19 infection; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for blood cancers and solid tumors. The company has a collaboration agreement with Sanofi. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands. As of April 12, 2021, Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "state": null,
        "city": "Amsterdam",
        "zipcode": "1105 BP",
        "website": "http://www.kiadis.com",
        "market_cap": "Micro Cap"
    },
    "KDS.AS": {
        "short_name": "KIADIS",
        "long_name": "Kiadis Pharma N.V.",
        "summary": "Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. It develops K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol; and K-NK003 for the treatment of patients with acute myeloid leukemia relapse/refractory. The company also develops K-NK-ID101 for the treatment of COVID-19 infection; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for blood cancers and solid tumors. The company has a collaboration agreement with Sanofi. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands. As of April 12, 2021, Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Netherlands",
        "state": null,
        "city": "Amsterdam",
        "zipcode": "1105 BP",
        "website": "http://www.kiadis.com",
        "market_cap": "Micro Cap"
    },
    "LVTX": {
        "short_name": "LAVA Therapeutics N.V.",
        "long_name": "Lava Therapeutics B.V.",
        "summary": "Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "state": null,
        "city": "Utrecht",
        "zipcode": "3584 CM",
        "website": "http://www.lavatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "MRUS": {
        "short_name": "Merus N.V.",
        "long_name": "Merus N.V.",
        "summary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Netherlands",
        "state": null,
        "city": "Utrecht",
        "zipcode": "3584 CM",
        "website": "http://www.merus.nl",
        "market_cap": "Small Cap"
    },
    "PHAR": {
        "short_name": "Pharming Group N.V.",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Netherlands",
        "state": null,
        "city": "Leiden",
        "zipcode": "2333 CR",
        "website": "http://www.pharming.com",
        "market_cap": "Small Cap"
    },
    "PHARM.AS": {
        "short_name": "PHARMING GROUP",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Netherlands",
        "state": null,
        "city": "Leiden",
        "zipcode": "2333 CR",
        "website": "http://www.pharming.com",
        "market_cap": "Small Cap"
    },
    "PHG.F": {
        "short_name": "PHARMING GRP SP. ADRS",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "state": null,
        "city": "Leiden",
        "zipcode": "2333 CR",
        "website": "http://www.pharming.com",
        "market_cap": "Small Cap"
    },
    "PHGN.F": {
        "short_name": "PHARMING GRP  EO-,01",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "state": null,
        "city": "Leiden",
        "zipcode": "2333 CR",
        "website": "http://www.pharming.com",
        "market_cap": "Small Cap"
    },
    "PHGUF": {
        "short_name": "PHARMING GROUP NV",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Netherlands",
        "state": null,
        "city": "Leiden",
        "zipcode": "2333 CR",
        "website": "http://www.pharming.com",
        "market_cap": "Small Cap"
    },
    "PHVS": {
        "short_name": "Pharvaris N.V.",
        "long_name": "Pharvaris B.V.",
        "summary": "Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "state": null,
        "city": "Leiden",
        "zipcode": "2333 CH",
        "website": "http://www.pharvaris.com",
        "market_cap": "Small Cap"
    },
    "PRQR": {
        "short_name": "ProQR Therapeutics N.V.",
        "long_name": "ProQR Therapeutics N.V.",
        "summary": "ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "state": null,
        "city": "Leiden",
        "zipcode": "2333 Ck",
        "website": "http://www.proqr.com",
        "market_cap": "Small Cap"
    },
    "QURE": {
        "short_name": "uniQure N.V.",
        "long_name": "uniQure N.V.",
        "summary": "uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "state": null,
        "city": "Amsterdam",
        "zipcode": "1105 BP",
        "website": "http://www.uniqure.com",
        "market_cap": "Small Cap"
    },
    "UQ1.DE": {
        "short_name": "UNIQURE N.V.  EO -,05",
        "long_name": "uniQure N.V.",
        "summary": "uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Netherlands",
        "state": null,
        "city": "Amsterdam",
        "zipcode": "1105 BP",
        "website": "http://www.uniqure.com",
        "market_cap": "Small Cap"
    },
    "UQ1.F": {
        "short_name": "UNIQURE N.V.  EO -,05",
        "long_name": "uniQure N.V.",
        "summary": "uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "state": null,
        "city": "Amsterdam",
        "zipcode": "1105 BP",
        "website": "http://www.uniqure.com",
        "market_cap": "Small Cap"
    }
}